{
  "docId": "019de073-8778-764b-accb-e5886cb9e840",
  "docSlug": "a27c0c380497fe380fc0ea99c606f1fe",
  "documentTitle": "Equillium | Results Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 32,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 24,
  "notes": "Data includes age, gender, race, country, disease duration, treatment history, LN class, and renal function metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8778-764b-accb-e5886cb9e840/22",
  "deckHref": "/decks/019de073-8778-764b-accb-e5886cb9e840",
  "deckJsonHref": "/decks/019de073-8778-764b-accb-e5886cb9e840.json",
  "deckAnchorHref": "/decks/019de073-8778-764b-accb-e5886cb9e840#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.12,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "1 UPCR measured by spot collections were highly correlated to 24-hour collection, r > 0.9. 2 Based on a mean of 2 values where available. Based on interim data from 2 Sep 2022 - subject to change. Abbreviations: SLE systemic lupus erythematosus, eGFR estimated glomerular filtration rate; LN lupus nephritis; SD standard deviation; US United States",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f427c04d-171f-43ad-aa58-5fa88965aec7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.93,
        "x": 0.035,
        "y": 0.18
      },
      "kind": "table",
      "text": "Baseline Characteristics of Safety Population (n=13)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f817e601-784f-4015-9e31-64f5365818d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.29,
        "x": 0.035,
        "y": 0.07
      },
      "kind": "title",
      "text": "Key Demographics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9008a6fd-a96e-480a-90cf-bcc1148d51b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "1abddc2d-3323-4e24-8358-1306d4fc9311",
      "evidence": "table/data: Baseline Characteristics of Safety Population (n=13)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 10,
      "beatId": "74c9ceff-f718-432a-b48e-9f41e627272b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Itolizumab's potential solution is presented, with efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 31,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f935949f-a063-4f53-ae76-c20f25bdff22",
      "evidence": "The presentation implies the cost of inaction through the unmet medical need and limitations of current treatments.",
      "position": 0,
      "objective": "What is the cost of not treating Lupus Nephritis effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5a9857ab-edc2-421f-aac9-92c4e50656db",
      "evidence": "The presentation discusses itolizumab's mechanism of action and efficacy in treating Lupus Nephritis.",
      "position": 1,
      "objective": "What are the jobs to be done in treating Lupus Nephritis?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}